

Le CHU de Toulouse au congrès ASCO 2023 à Chicago

I. **Poster Session**

- 1. Preliminary results of a phase 1, first-in-human study of INA03, an anti-CD71 antibody-drug conjugate, in patients with relapsed or refractory (R/R) acute leukemias.**
Sylvain Garciaz, Pierre Bories, Leonor Lopez Almeida, Jean-Marie Boher, Coralie Belanger, **Christian Recher**, Olivier Hermine, Norbert Vey, Pierre Launay [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
- 2. Avelumab as second-line or later (2L+) treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Analysis of real-world outcomes in France using the CARADERM registry and the French national healthcare database.**
Astrid Blom Fily, Laurent Mortier, Isabelle Kachaner, **Nicolas Meyer**, Mahtab Samimi, Laura Luciani, Capucine Cahuzac, Caroline Robert, Gaëlle Quéreux, Eve Maubec, Cathy Maillard, Hakima Miotti, François Aubin, Cédric Lenormand, Marie-Noëlle Solbes, Pascal Joly, Benoît van Hille, Celeste Lebbe, Caroline Dutriaux, Philippe Saiag [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
- 3. Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).** Cyrille Touzeau, Xavier Leleu, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, **Benjamin Hebraud**, Olivier Decaux, Samantha Schulmann, Caroline Lenoir, Pascal Godmer, Agathe Farge, Laure Peyro Saint Paul, Jean-Jacques Parienti, Margaret Macro [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
- 4. Disease-free survival in operated patients with nmRCC using machine learning.** Gaëlle Margue, Loïc Ferrer, Guillaume Etchepare, Pierre Bigot, Karim Bensalah, Arnaud Mejean, Morgan Roupert, **Nicolas Doumerc**, Alexandre Ingels, Romain Boissier, Geraldine Pignot, Bastien Parier, Philippe Paparel, Thibaut Waeckel, Thierry Colin, Jean-Christophe Bernhard [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
- 5. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.** Dinu Stefan, Justine Lequesne, Sunyach Marie, Delphine Larrieu-Ciron, Charlotte Bronnimann, Loic Feuvret, Julien Geffrelot, Jeanne Riverain, Pierre-Emmanuel Brachet, Joelle Lacroix, Fernand Missohou, Maxime Faisant, Evelyne Emery, Elisabeth Moyal, Bérénice Legrand, Gwenaëlle Boudier, Marie Castera, Jean-Michel Grellard, Paul Lesueur, Benedicte Clarisse [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
- 6. Long-term outcomes of tepotinib in patients with MET exon 14 skipping NSCLC from the VISION study.** Paul Paik, Marina Garassino, Xiuning Le, Michael Thomas, Hiroshi Sakai, Remi Veillon, Egbert Smit, **Julien Mazières**, Alexis Cortot, Jo Raskin, Santiago Viteri, James Chih-Hsin

Yang, Myung-Ju Ahn, Yi-Long Wu, Jun Zhao, Svenja Adrian, Karin Berghoff, Rolf Bruns, Andreas Johne, Enriqueta Felip [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

7. **Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.** Helena Yu, Keith Kerr, Christian Rolfo, Jian Fang, Giovanna Finocchiaro, Kam-Hung Wong, Remi Veillon, Terufumi Kato, James Chih-Hsin Yang, Ernest Nadal, Jo Raskin, Xiuning Le, Niki Karachaliou, Barbara Ellers-Lenz, Aurora OBrate, Christopher Stroh, Nadine Piske, Carsten Boesler, Jinji Yang, **Julien Mazières** [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
8. **Explore ALK: Alectinib activity in patients with ALK+ metastatic non-small cell lung cancer— A national real world analysis (GFPC 03-2019).** Aurélie Swalduz, Gaëlle Rousseau-Bussac, Florian Guisier, Helene Doubre, Pierre Fournel, Lionel Falchero, Laurence **Bigay Game**, Remi Veillon, Marie Marcq, Charles Ricordel, Chantal Decroisette, Domitille Dano, Gregoire Justeau, Stéphanie Martinez, Alexis Cortot, Hugues Morel, Laurent Greillier, Renaud Descourt [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
9. **Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).** George Lau, Bruno Sangro, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Lipatov, Manabu Morimoto, Isabelle Archambeaud, Valentina Burgio, Le Thi Tuyet Phuong, Yee Chao, **Jean-Marie Peron**, Marie-Luise Berres, Yoo-Joung Ko, Carrie McCoy, Charu Gupta, Mallory Makowsky, Alejandra Negro, Ghassan Abou-Alfa [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
10. **Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.** Xiuning Le, Anna Eisert, Te-Chun Hsia, Nirmal Raut, Azura Ahmad, Oscar Chan, Charlotte De Bondt, David Farrugia, Patrizia Froesch, Maria González-Cao, Lizza Hendriks, Maximilian Hochmair, **Julien Mazieres**, Hazel O’Sullivan, Jens Samol, Anthonie van der Wekken, Tsung-Ying Yang, Kirti Joshi, Soetkin Vlassak, Gee-Chen Chang [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)
11. **Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).** Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houllier, **Lucie Oberic**, Olivier L. Chinot, Franck Morschhauser, Frederic Peyrade, Roch Houot, Christine Foulon, Estelle Chauvin, Herve Ghesquieres, Carole Soussain [Poster Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

II. **Poster Discussion Session**

12. **Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib.** Daniel Tan, Tae Min Kim, Valentina Guarneri, PEI JYE VOON, Boon Khaw Lim, Marie Wislez, Cheng Huang, Chong Kin Liam, **Julien Mazieres**, Lye Tho, Hidetoshi Hayashi, Nguyen Nhung, Puey Chia, Filippo de Marinis, Xiuning Le, Niki Karachaliou, Sabine Brutlach, Svenja Adrian, Barbara Eilers-Lenz, Yi-Long Wu [Poster Discussion Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

13. **Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.** Stéphane De Botton, Pau Montesinos, Susana Vives Polo, Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo Calado, Andre Schuh, Su-Peng Yeh, Jianan Hui, Diego Gianolio, Prapti Patel, **Christian Recher**, Hartmut Dohner [Poster Discussion Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

14. **Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).** Maximiliano Gelli, Jacques Ewald, Marie Laure Tanguy, Guillaume Passot, Francois Quenet, Yann Toucheffeu, Hélène Senellart, **Fabrice Muscari**, Astrid Lievre, René Adam, Thomas Aparicio, Julien Taieb, Charles Mastier, Jean-Marc Regimbeau, Amani Asnacios Lecerf, David Tougeron, Valerie Boige, Thierry De Baere, David Malka, Diane Goere [Poster Discussion Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

III. **Publication Only**

15. **Prediction of brain metastases progression and overall survival in patients with metastatic non-small cell lung cancer treated by immune checkpoint inhibitors using a radiomic model.** Clemence Henon, Lizza Hendriks, Alexandre Carré, Laura Mezquita, Sylvain Reuzé, Samy Ammari, Mihaela Aldea, Charlotte Robert, Cecile Le Pechoux, Clarisse Audigier-Valette, **Julien Mazières**, Corentin Lefebvre, **Audrey Rabeau**, Boris Duchemann, Angela Botticella, David Planchard, Eric Deutsch, Benjamin Besse, Roger Sun [Publication Only](#)
[Program Guide – ASCO Meeting Program Guide](#)

16. **Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas.** Eve Maubec, Marouane Boubaya, Lydia Deschamps, Marie Beylot-Barry, Peter Petrow, Isabelle Scheer-Senarich, Nicole Basset-Seguín, Jean-Jacques Grob, Brigitte Dreno, Coralie Bloch-Queyrat, Marie Leccia, Andreea Raluca Stefan, Philippe Saiag, Florent Grange, **Nicolas Meyer**, Sophie Dalac, Céline Alloux, Isabelle Lopez, Annick Tibi, Vincent Lévy [Publication Only](#)
[Program Guide – ASCO Meeting Program Guide](#)

IV. **Oral Abstract Session**

17. **Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.** Charles Rudin, Hye Ryun Kim, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csoszi, Parneet Cheema, Delvys Rodriguez-Abreu, Mira Wollner, James Chih-Hsin Yang, **Julien Mazieres**, Terufumi Kato, Gregory Kalemkerian, Elisha Dettman, Mackenzie Edmondson, Amir Vajdi, Andrey Loboda, Hazem El-Osta, Bin Zhao, Mark Awad [Oral Abstract Session](#)

[Program Guide – ASCO Meeting Program Guide](#)

18. **Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.** Clémentine Sarkozy, Catherine Thieblemont, **Lucie Oberic**, Anne Moreau, Krimo Bouabdallah, Gandhi Laurent Damaj, Thomas Gastinne, Olivier Casasnovas, Corinne Haioun, Roch Houot, Eric Van Den Neste, Morgane Cheminant, Herve Ghesquieres, Vincent Ribrag, Franck Morschhauser, Mary Callanan, Remi Gressin, Olivier Hermine, Steven Le Gouill, Fabrice Jardin. [Oral Abstract Session](#)
[Program Guide – ASCO Meeting Program Guide](#)

V. Clinical Science Symposium (oral)

19. **Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).** Lisa Derosa, Carolina Silva, Valerio Iebba, Bertrand Routy, Anna Reni, Clarisse Audigier-Valette, Gerard Zalzman, **Julien Mazières**, Sylvie Friard, François Goldwasser, Denis MORO SIBILOT, Arnaud Scherpereel, Herve Pegliasco, Stéphanie Martinez, Bernard Escudier, David Planchard, Laurence Albiges, Benjamin Besse, Fabrice Barlesi, Laurence Zitvogel [Clinical Science Symposium](#)
[Program Guide – ASCO Meeting Program Guide](#)

VI. Rapid Abstract Session (oral)

20. **Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.** Filippo Dall'Olio, Damien Vasseur, Maryam Karimi, Stefan Michiels, Ludovic Lacroix, Pascale Tomasini, Judith Raimbourg, Noemie pata-Merci, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Ivan Bieche, **Julien Mazières**, Denis MORO SIBILOT, Marta Jimenez, Jean-Charles Soria, Virginie Westeel, Fabrice Barlesi, Benjamin Besse [Rapid Abstract Session](#)
[Program Guide – ASCO Meeting Program Guide](#)